Clinical Trial

Clinical Effectiveness and Safety of SHR-A1811 in Chinese Patients With HER2-Altered NSCLC

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
SHR-A1811 is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of SHR-A1811 used in Chinese lung cancer patients with HER2 alteration. This real world, prospective study will assess the effectiveness and safety of SHR-A1811 in patients with locally advanced or metastatic, HER2-Altered NSCLC in real-world setting.
Trial Details
NCT Number NCT07516015
Lead Sponsor Nanjing Tianyinshan Hospital
Collaborators: Henan Cancer Hospital
Conditions NSCLC
Enrollment 1,000 participants
Start Date 2026-04-10
Primary Completion 2029-09-30 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-07